Management of CML-blast crisis
Tyrosine kinase inhibitors (TKI) have moderately improved survival in BC, but a median survival of less than 1 year is still unsatisfactory. This article reviews the various tests required for diagnosis of BC, features at diagnosis, treatment modalities (intensive chemotherapy, TKI, allo-SCT and a s...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2016
|
| In: |
Best practice & research
Year: 2016, Jahrgang: 29, Heft: 3, Pages: 295-307 |
| ISSN: | 1532-1924 |
| DOI: | 10.1016/j.beha.2016.10.005 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.beha.2016.10.005 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1521692616300585 
|
| Verfasserangaben: | Rüdiger Hehlmann, Susanne Saußele, Astghik Voskanyan, Richard T. Silver |
| Zusammenfassung: | Tyrosine kinase inhibitors (TKI) have moderately improved survival in BC, but a median survival of less than 1 year is still unsatisfactory. This article reviews the various tests required for diagnosis of BC, features at diagnosis, treatment modalities (intensive chemotherapy, TKI, allo-SCT and a selection of investigational agents), options of prevention and predictors of progression. The best prognosis is observed in patients that achieve a 2nd CP. Allo-SCT probably further improves prognosis of patients in 2nd CP. The choice of TKI should be directed by the mutation profile of the patient. BC can be prevented. A careful analysis of risk factors for progression may help. Current treatment options are combined in a concluding strategy for the management of BC. |
|---|---|
| Beschreibung: | Gesehen am 06.08.2019 Available online 20 October 2016 |
| Beschreibung: | Online Resource |
| ISSN: | 1532-1924 |
| DOI: | 10.1016/j.beha.2016.10.005 |